A Randomized, Placebo-Controlled, Single-Blind, Dose-Escalation, First-Time-in-Human Study to Assess the Safety and Pharmacokinetics of Single and Repeat Doses of SRT3025 in Normal Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs SRT 3025 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Sirtris
- 17 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2011 Planned number of patients changed from 86 to 78 as reported by ClinicalTrials.gov.